These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date 2006-001488-51 A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY, TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF THE MGLUR5 NEGATIVE ALLOSTERIC MODULATOR ADX10059 IN THE ACUTE TREATMENT OF MIGRAINE 2006-12-20 bad-data
Not reported 2006-003912-23 A Phase IIa, double-blind, placebo-controlled, randomised, parallel-group study, to investigate the safety, tolerability and anxiolytic effect of the mGluR5 negative allosteric modulator ADX10059 in p... 2007-12-03 due-trials
Listed as ongoing, but also has a completion date 2008-005104-10 A phase 2B, randomised, double-blind, placebo-controlled, parallel group, multi-centre study to investigate the efficacy, mechanism of action, pharmacokinetics, safety and tolerability of the mGluR5 n... 2009-10-16 bad-data
Listed as ongoing, but also has a completion date 2008-005105-18 A phase 2B, randomised, double-blind, placebo-controlled, parallel group, dose-ranging, multi-centre study to investigate the efficacy, safety and tolerability of the mGluR5 negative allosteric modula... 2009-12-11 bad-data
Listed as ongoing, but also has a completion date 2008-005481-30 A phase 2B, randomised, double-blind, placebo-controlled, parallel group, dose-ranging, multicentre study to investigate the efficacy, safety and tolerability of the mGluR5 negative allosteric modulat... 2009-12-14 bad-data
Listed as ongoing, but also has a completion date 2010-022517-25 Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety, tolerability and efficacy of ADX48621 in the treatment of levodopa induced dyskinesia i... 2012-09-17 bad-data